Still Waiting for Answers
Amid the finger-pointing, hand-wringing, and bloviating, the supply of hard, technical information remains frustratingly small.
Articles in this issue
Still Waiting for Answers
Method Validation by Phase of Development: An Acceptable Analytical Practice
Comparing and Contrasting Barrier Isolator Decontamination Systems
November 2004
In the Spotlight-November 2004
Searching for a Viable Business Model
Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development
FDA Moves To Implement New GMP Policies
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Article
Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
